DR. REDDY'S LABORATORIES LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,462 INR | +1.43% |
|
+6.62% | +11.59% |
| Jul. 01 | Asian Equities Traded in the US as American Depositary Receipts Open Week on Flat Note | MT |
| Jun. 28 | Dr. Reddy's to Co-market Zydus' Breast Cancer Treatment in India | MT |
| Sales 2025 * | 303B 3.63B | Sales 2026 * | 325B 3.9B | Capitalization | 1,061B 12.71B |
|---|---|---|---|---|---|
| Net income 2025 * | 55.14B 660M | Net income 2026 * | 56.71B 679M | EV / Sales 2025 * | 3.2 x |
| Net cash position 2025 * | 91.02B 1.09B | Net cash position 2026 * | 127B 1.52B | EV / Sales 2026 * | 2.87 x |
| P/E ratio 2025 * |
19.1
x | P/E ratio 2026 * |
18.6
x | Employees | 27,048 |
| Yield 2025 * |
0.63% | Yield 2026 * |
0.63% | Free-Float | 70.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on Dr. Reddy's Laboratories Limited
More recommendations
More press releases
More news
| 1 day | +1.94% | ||
| 1 week | +7.03% | ||
| Current month | +1.39% | ||
| 1 month | +12.29% | ||
| 3 months | +6.08% | ||
| 6 months | +9.51% | ||
| Current year | +12.02% |
1 week
5 999.85
6 512.00
1 month
5 600.056 512.00
Current year
5 523.456 512.00
1 year
5 042.656 512.00
3 years
3 655.006 512.00
5 years
2 352.006 512.00
10 years
1 888.006 512.00
| Managers | Title | Age | Since |
|---|---|---|---|
Erez Israeli
CEO | Chief Executive Officer | 57 | 18-04-01 |
Parag Agarwal
DFI | Director of Finance/CFO | - | 20-11-01 |
| Chairman | 56 | 93-01-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gunupati Prasad
CHM | Chairman | 63 | 86-04-07 |
| Chairman | 56 | 93-01-17 | |
Kalpana Morparia
BRD | Director/Board Member | 74 | 07-06-04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.02% | 6 M€ | +6.07% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-03 | 6,462 | +1.43% | 20 733 |
| 24-07-02 | 6,372 | +0.32% | 11,243 |
| 24-07-01 | 6,352 | -0.85% | 17,400 |
| 24-06-28 | 6,406 | +2.66% | 45,349 |
| 24-06-27 | 6,240 | +2.82% | 39,471 |
Delayed Quote Bombay S.E., July 03, 2024 at 02:13 am EDT
More quotes
Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows:
- sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines;
- sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services;
- other (4.4%): sales of generic biopharmaceutical products, development of molecular agents, etc.
Net sales are distributed geographically as follows: India (18.8%), the United States (45%), Russia (9.9%) and other (26.3%).
Sector
Pharmaceuticals
Calendar
2024-07-15
- Détachement de for final dividend
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
36
Last Close Price
6,372
INR
Average target price
6,161
INR
Spread / Average Target
-3.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.02% | 12.71B | |
| +55.55% | 816B | |
| +42.31% | 634B | |
| -6.83% | 351B | |
| +17.15% | 323B | |
| +7.09% | 293B | |
| +14.02% | 238B | |
| +1.64% | 222B | |
| +13.66% | 218B | |
| +7.87% | 167B |
- Stock Market
- Equities
- DRREDDY Stock
